Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022
29.09.2022 - Carlsbad, CA, Sept. 29, 2022 (GLOBE NEWSWIRE) - Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted ...
Source: wallstreet-online.de